Electroporation-mediated HGF gene transfection protected the kidney against graft injury.

Abstract:

:The annual rate of kidney graft loss caused by chronic allograft nephropathy (CAN) has not improved over the past decade. Recent reports suggest that acute renal ischemia results in development of CAN. The goal of the present study was to assess the renoprotective potential and safety of hepatocyte growth factor (HGF) gene transfer using a porcine kidney transplant warm ischemia injury model. Following left porcine kidney removal, 10 min of warm ischemic injury was intentionally induced. Next, the HGF expression vector or vehicle was infused into the renal artery with the renal vein clamped ex vivo, and electric pulses were discharged using bathtub-type electrodes. Kidney grafts were then transplanted after removing the right kidney. Histopathological examination of vehicle-transfected kidney transplant revealed initial tubular injury followed by tubulointerstitial fibrosis. In contrast, HGF-transfected kidneys showed no initial tubular damage and no interstitial fibrosis at 6 months post-transplant. We conclude that electroporation-mediated ex vivo HGF gene transfection protects the kidney against graft injury in a porcine model.

journal_name

Gene Ther

journal_title

Gene therapy

authors

Isaka Y,Yamada K,Takabatake Y,Mizui M,Miura-Tsujie M,Ichimaru N,Yazawa K,Utsugi R,Okuyama A,Hori M,Imai E,Takahara S

doi

10.1038/sj.gt.3302478

subject

Has Abstract

pub_date

2005-05-01 00:00:00

pages

815-20

issue

10

eissn

0969-7128

issn

1476-5462

pii

3302478

journal_volume

12

pub_type

杂志文章
  • Chitosan-plasmid nanoparticle formulations for IM and SC delivery of recombinant FGF-2 and PDGF-BB or generation of antibodies.

    abstract::Growth factor therapy is an emerging treatment modality that enhances tissue vascularization, promotes healing and regeneration and can treat a variety of inflammatory diseases. Both recombinant human growth factor proteins and their gene therapy are in human clinical trials to heal chronic wounds. As platelet-derived...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2009.60

    authors: Jean M,Smaoui F,Lavertu M,Méthot S,Bouhdoud L,Buschmann MD,Merzouki A

    更新日期:2009-09-01 00:00:00

  • In vivo targeted delivery of CD40 shRNA to mouse intestinal dendritic cells by oral administration of recombinant Sacchromyces cerevisiae.

    abstract::Short hairpin RNA (shRNA)-mediated gene regulation is a commonly used technique for gene manipulation. An efficient and safe delivery system is indispensable when shRNA is delivered into living organisms for gene therapy. Previous studies have proved that DNA and protein can be delivered into dendritic cells (DCs) by ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2014.50

    authors: Zhang L,Zhang T,Wang L,Shao S,Chen Z,Zhang Z

    更新日期:2014-07-01 00:00:00

  • Immune response to green fluorescent protein: implications for gene therapy.

    abstract::Green fluorescent protein (GFP) is a widely used intracellular reporter molecule to assess gene transfer and expression. A potential use for GFP is as a co-expressed marker, to select and enrich gene-modified cells by flow cytometry. Processed peptides derived from GFP and presented by the major histocompatibility com...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300951

    authors: Stripecke R,Carmen Villacres M,Skelton D,Satake N,Halene S,Kohn D

    更新日期:1999-07-01 00:00:00

  • Gene-based approaches for the repair of articular cartilage.

    abstract::Gene transfer technology has opened novel treatment avenues toward the treatment of damaged musculoskeletal tissues, and may be particularly beneficial to articular cartilage. There is no natural repair mechanism to heal damaged or diseased cartilage. Existing pharmacologic, surgical and cell based treatments may offe...

    journal_title:Gene therapy

    pub_type: 杂志文章,评审

    doi:10.1038/sj.gt.3302201

    authors: Trippel SB,Ghivizzani SC,Nixon AJ

    更新日期:2004-02-01 00:00:00

  • Adenovirus-mediated transfer of the p53 family genes, p73 and p51/p63 induces cell cycle arrest and apoptosis in colorectal cancer cell lines: potential application to gene therapy of colorectal cancer.

    abstract::p53 gene therapy is being tested clinically for the treatment of human cancer, however, some cancer models (in vivo and in vitro) are resistant to p53. To explore the potential use of two p53 homologues, p73 and p51/p63, in cancer gene therapy, we introduced p53, p73 and p51/p63 into colorectal cancer cell lines via a...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301538

    authors: Sasaki Y,Morimoto I,Ishida S,Yamashita T,Imai K,Tokino T

    更新日期:2001-09-01 00:00:00

  • A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases.

    abstract::The GM2-gangliosidoses are neurological diseases causing premature death, thus developing effective treatment protocols is urgent. GM2-gangliosidoses result from deficiency of a lysosomal enzyme β-hexosaminidase (Hex) and subsequent accumulation of GM2 gangliosides. Genetic changes in HEXA, encoding the Hex α subunit,...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/s41434-019-0120-5

    authors: Ou L,Przybilla MJ,Tăbăran AF,Overn P,O'Sullivan MG,Jiang X,Sidhu R,Kell PJ,Ory DS,Whitley CB

    更新日期:2020-05-01 00:00:00

  • PML has a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses.

    abstract::The oncotropic phenotypes of several viruses correlate with tumor-associated deficiencies within interferon (IFN) signaling pathways. This observation formed the conceptual basis for developing oncolytic viruses deleted for viral proteins that inhibit the host IFN-dependent antiviral response, such as herpes simplex v...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2009.68

    authors: Sobol PT,Hummel JL,Rodrigues RM,Mossman KL

    更新日期:2009-09-01 00:00:00

  • Technical requirements for effective regional hydrodynamic gene delivery to the left lateral lobe of the rat liver.

    abstract::Hydrodynamic gene delivery to the liver is an attractive approach for clinical liver gene therapy, but critical aspects of technique remain uncertain. There has not been to date any report of high levels of hydrodynamic gene delivery to the liver, except in rodents. Regional hydrodynamic delivery to individual lobes/s...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2009.167

    authors: Sawyer GJ,Zhang X,Fabre JW

    更新日期:2010-04-01 00:00:00

  • Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes.

    abstract::Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates blood glucose level post-prandially. It has been proposed that GLP-1 can be used in type 2 diabetes (T2D) mellitus treatment because of its insulinotropic action. Despite its remarkable advantages, GLP-1 suffers the disadvantage of an extremely shor...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2011.25

    authors: Jean M,Alameh M,Buschmann MD,Merzouki A

    更新日期:2011-08-01 00:00:00

  • Low-speed centrifugation of retroviral vectors absorbed to a particulate substrate: a highly effective means of enhancing retroviral titre.

    abstract::For many gene therapy applications the effective titre of retroviral vectors is a limiting factor both in vitro and in vivo. Purification and concentration of retrovirus from packaging cell supernatant can overcome this problem. To this end we have investigated a novel procedure which involves complexing retrovirus to...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301201

    authors: Darling D,Hughes C,Galea-Lauri J,Gäken J,Trayner ID,Kuiper M,Farzaneh F

    更新日期:2000-06-01 00:00:00

  • Progress and prospects: oligonucleotide-directed gene modification in mouse embryonic stem cells: a route to therapeutic application.

    abstract::Gene targeting by single-stranded oligodeoxyribonucleotides (ssODNs) is a promising technique for introducing site-specific sequence alterations without affecting the genomic organization of the target locus. Here, we discuss the significant progress that has been made over the last 5 years in unraveling the mechanism...

    journal_title:Gene therapy

    pub_type: 杂志文章,评审

    doi:10.1038/gt.2010.161

    authors: Aarts M,te Riele H

    更新日期:2011-03-01 00:00:00

  • Establishment of complement-resistant retroviral vector by homologous restriction factor 20 gene.

    abstract::Homologous restriction factor 20 (HRF20, CD59) is one of the complement regulatory factors. In this study, the complement-resistant retroviral vector, which possesses the HRF20 gene as a selection gene, was constructed and examined. The virus-producing cell, transduced with complement-resistant retroviral vector, was ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300574

    authors: Hayashi S,Emi N,Okada H,Nagasaka T,Yokoyama I,Takagi H

    更新日期:1998-02-01 00:00:00

  • Percutaneous gene therapy heals cranial defects.

    abstract::Nonhealing bone defects are difficult to treat. As the bone morphogenic protein and transforming growth factor beta pathways have been implicated in bone healing, we hypothesized that percutaneous Smad7 silencing would enhance signaling through both pathways and improve bone formation. Critical sized parietal trephine...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2013.15

    authors: Layliev J,Sagebin F,Weinstein A,Marchac A,Szpalski C,Saadeh PB,Warren SM

    更新日期:2013-09-01 00:00:00

  • Human cytidine deaminase as an ex vivo drug selectable marker in gene-modified primary bone marrow stromal cells.

    abstract::Naturally occurring drug resistance genes of human origin can be exploited for selection of genetically engineered cells co-expressing a desired therapeutic transgene. Their non-immunogenicity in clinical applications would be a major asset. Human cytidine deaminase (hCD) is a chemoresistance gene that inactivates cyt...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301675

    authors: Eliopoulos N,Al-Khaldi A,Beauséjour CM,Momparler RL,Momparler LF,Galipeau J

    更新日期:2002-04-01 00:00:00

  • Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment.

    abstract::The canine is the most important large animal model for testing novel hemophilia A (HA) treatment. It is often necessary to use canine factor VIII (cFIII) gene or protein for the evaluation of HA treatment in the canine model. However, different biological properties between cFVIII and human FVIII (hFVIII) indicated t...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2016.34

    authors: Wang Q,Dong B,Firrman J,Wu W,Roberts S,Moore AR,Liu LS,Chin MP,Diao Y,Kost J,Xiao W

    更新日期:2016-07-01 00:00:00

  • Functional correction of T cells derived from patients with the Wiskott-Aldrich syndrome (WAS) by transduction with an oncoretroviral vector encoding the WAS protein.

    abstract::T-cell dysfunction is thought to be central to the immunodeficiency state seen in patients with the Wiskott-Aldrich syndrome (WAS). Aspects of the WAS phenotype have been corrected in other cell types on introduction of the normal WAS protein (WASP), but the potential for correction of the T-cell defects has not been ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301950

    authors: Strom TS,Gabbard W,Kelly PF,Cunningham JM,Nienhuis AW

    更新日期:2003-05-01 00:00:00

  • GCV phosphates are transferred between HeLa cells despite lack of bystander cytotoxicity.

    abstract::The role of gap junctional intercellular communication (GJIC) in bystander killing with herpes simplex virus thymidine kinase (HSV-TK) and ganciclovir (GCV) was evaluated in U251 cells expressing a dominant-negative connexin 43 cDNA (DN14), and in HeLa cells, reportedly devoid of connexin protein. These cell lines bot...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302487

    authors: Gentry BG,Im M,Boucher PD,Ruch RJ,Shewach DS

    更新日期:2005-07-01 00:00:00

  • Gene therapy in transplantation in the year 2000: moving towards clinical applications?

    abstract::Transplantation faces several major obstacles that could be overcome by expression of immunomodulatory proteins through application of gene therapy techniques. Gene therapy strategies to prolong graft survival involve gene transfer of immunosuppressive or graft-protecting molecules. Very promising results have been ob...

    journal_title:Gene therapy

    pub_type: 杂志文章,评审

    doi:10.1038/sj.gt.3301083

    authors: Guillot C,Le Mauff B,Cuturi MC,Anegon I

    更新日期:2000-01-01 00:00:00

  • Pre-emptive gene therapy using recombinant adeno-associated virus delivery of extracellular superoxide dismutase protects heart against ischemic reperfusion injury, improves ventricular function and prolongs survival.

    abstract::In high-risk patients, the ideal cardiovascular gene therapy requires a strategy that provides long-term protection of myocardium against episodes of ischemic/reperfusion injury. We report the development of an efficient, long-lasting pre-emptive gene therapy strategy in a rat model of ischemic-reperfusion (I/R) injur...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302250

    authors: Agrawal RS,Muangman S,Layne MD,Melo L,Perrella MA,Lee RT,Zhang L,Lopez-Ilasaca M,Dzau VJ

    更新日期:2004-06-01 00:00:00

  • Incorporation of beta-globin untranslated regions into a Sindbis virus vector for augmentation of heterologous mRNA expression.

    abstract::Polynucleotide immunization has been employed as a means of inducing immune responses through the introduction of antigen-encoding DNA. While immunization against specific tumor antigens may be achieved through this strategy, various candidate tumor antigens may not be approached via DNA-based vaccines as they represe...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300423

    authors: Strong TV,Hampton TA,Louro I,Bilbao G,Conry RM,Curiel DT

    更新日期:1997-06-01 00:00:00

  • Retrovirus-mediated gene transfer in lungs of living fetal sheep.

    abstract::In utero somatic gene transfer may be a useful therapeutic strategy for a variety of inherited disorders. In the present study, we demonstrate transgene expression in the airways of fetal lamb lungs, 2-3 weeks after injection of Moloney murine leukemia retrovirus based vectors containing cDNA for beta-galactosidase (l...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:

    authors: Pitt BR,Schwarz MA,Pilewski JM,Nakayama D,Mueller GM,Robbins PD,Watkins SA,Albertine KH,Bland RD

    更新日期:1995-07-01 00:00:00

  • New tools for the generation of E1- and/or E3-substituted adenoviral vectors.

    abstract::We have designed new vectors for the construction of recombinant adenoviruses containing expression cassettes in the E1 and/or E3 regions. Using a versatile set of restriction enzymes, the cassettes are cloned into small bacterial vectors and subsequently introduced into large plasmids containing the adenoviral sequen...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301047

    authors: Danthinne X,Werth E

    更新日期:2000-01-01 00:00:00

  • Current progress in the development of RNAi-based therapeutics for HIV-1.

    abstract::Highly active antiretroviral therapy (HAART) treatment for HIV has changed the course of AIDS in societies in which the drugs are readily available. Despite the great success of HAART, drug resistance and toxicity issues still remain a concern for some individuals. Thus, a number of investigators have been exploring o...

    journal_title:Gene therapy

    pub_type: 杂志文章,评审

    doi:10.1038/gt.2011.149

    authors: Zhou J,Rossi JJ

    更新日期:2011-12-01 00:00:00

  • Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis.

    abstract::Active disease of tuberculosis (TB) can be developed decades later by either a relapse of the initial infection (endogenous reactivation) or by an entrance of the secondary infection (exogenous reinfection), since the current chemotherapy cannot lead to complete elimination of tuberculosis. Although the immunotherapeu...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302465

    authors: Ha SJ,Jeon BY,Youn JI,Kim SC,Cho SN,Sung YC

    更新日期:2005-04-01 00:00:00

  • Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva.

    abstract::Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant congenital disorder characterized by progressive heterotopic bone formation. Currently, no definitive treatment exists for FOP. The activin receptor type IA / activin-like kinase 2 (ACVR1/ALK2) gene has been identified as the responsible gene for FOP...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2011.193

    authors: Takahashi M,Katagiri T,Furuya H,Hohjoh H

    更新日期:2012-07-01 00:00:00

  • Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy.

    abstract::The sodium iodide symporter (NIS) mediates iodide uptake into thyrocytes and is the molecular basis of thyroid radioiodine therapy. We previously have shown that NIS gene transfer into the F98 rat gliomas facilitated tumor imaging and increased survival by radioiodine. In this study, we show that: (1) the therapeutic ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302147

    authors: Shen DH,Marsee DK,Schaap J,Yang W,Cho JY,Hinkle G,Nagaraja HN,Kloos RT,Barth RF,Jhiang SM

    更新日期:2004-01-01 00:00:00

  • Induction of complement attack on human cells by Gal(alpha1,3)Gal xenoantigen expression as a gene therapy approach to cancer.

    abstract::Galactose(alpha1,3)galactose on the surface of cells of non-primate organs is the major xenoantigen responsible for hyperacute rejection in xenotransplantation. The antigen is synthesised by (alpha1, 3)galactosyl transferase. Humans lack this enzyme and their serum contains high levels of pre-existing natural antibody...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300934

    authors: Jäger U,Takeuchi Y,Porter C

    更新日期:1999-06-01 00:00:00

  • T-cell response to adenovirus hexon and DNA-binding protein in mice.

    abstract::The successful development of adenovirus vectors for vaccines and gene therapy will require a better understanding of the host immune response. Using the ELISPOT assay to measure IFN-gamma-secreting CD8(+) cells, we identify immunodominant epitopes of the adenovirus hexon and DNA-binding protein in BALB/c and C57BL/6 ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302232

    authors: McKelvey T,Tang A,Bett AJ,Casimiro DR,Chastain M

    更新日期:2004-05-01 00:00:00

  • MnSOD mediated by HSV vectors in the periaqueductal gray suppresses morphine withdrawal in rats.

    abstract::Morphine appears to be the most active metabolite of heroin; therefore, the effects of morphine are important in understanding the ramifications of heroin abuse. Opioid physical dependence (withdrawal response) may have very long-lasting effects on the motivation for reward, including the incubation of cue-induced dru...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2017.22

    authors: Iida T,Yi H,Liu S,Ikegami D,Zheng W,Liu Q,Takahashi K,Kashiwagi Y,Goins WF,Glorioso JC,Hao S

    更新日期:2017-05-01 00:00:00

  • Articular cartilage repair by genetically modified bone marrow aspirate in sheep.

    abstract::Bone marrow presents an attractive option for the treatment of articular cartilage defects as it is readily accessible, it contains mesenchymal progenitor cells that can undergo chondrogenic differentiation and, once coagulated, it provides a natural scaffold that contains the cells within the defect. This study was p...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2010.16

    authors: Ivkovic A,Pascher A,Hudetz D,Maticic D,Jelic M,Dickinson S,Loparic M,Haspl M,Windhager R,Pecina M

    更新日期:2010-06-01 00:00:00